AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02967029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil Hydrochloride
Description: the influence of remifentanyl as a hypotensive agent on rSO2
Study NCT00564408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbachol
Description: 3 microgram per kg bodyweight infused intravenously
Study NCT02803450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural needle
Description: Medication administration via epidural needle.
Study NCT02803450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter Administration
Description: Medication administration via epidural catheter.
Study NCT02803450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Epidural Administration
Description: Medication administered at higher concentration, lower volume via epidural catheter.
Study NCT01316055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine-ER
Description: 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up
Study NCT00131391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: taranabant
Description: taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule. 52 week treatment period.
Study NCT00131391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: Placebo capsule once daily . 52 week treatment period.
Study NCT00131391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Placebo capsule once daily . 52 week treatment period.
Study NCT01450592 — intervention group
Intervention type: OTHER
Intervention: No drug
Description: Diabetic Population
Study NCT00690898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel 120 mg
Description: 12 months
Study NCT04002700 — intervention group
Intervention type: DRUG
Intervention: Haloperidol
Description: Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of haloperidol. No drug will be administered as part of this study.
Study NCT04002700 — intervention group
Intervention type: DRUG
Intervention: Typical Antipsychotics
Description: Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of typical antipsychotics which includes Haloperidol, Loxapine, Thioridazine, Molindone, Thiothixene, Fluphenazine, Trifluoperazine, Perphenazine, Chlorpromazine. No drug will be administered as part of this study.
Study NCT04002700 — intervention group
Intervention type: DRUG
Intervention: Atypical Antipsychotics
Description: Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of atypical antipsychotics which includes Aripriprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Paliperidone, Ziprasidone, Risperidone, Quetiapine, Olanzapine. No drug will be administered as part of this study.
Study NCT01360476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol (Vitamin D)
Description: 50,000 UI, chewable wafer every 2 weeks for 52 weeks (27 total doses)
Study NCT01360476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: chewable wafer every 2 weeks for 52 weeks (27 total doses)
Study NCT01450592 — intervention group
Intervention type: OTHER
Intervention: No drug
Description: Non-Diabetic Population
Study NCT01178931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral dydrogesterone
Description: oral-2x10mg
Study NCT01178931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crinone 8% gel
Description: vaginal-1x90mg
Study NCT04270773 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Human Papillomavirus 9-valent Vaccine, Recombinant
Description: Vaccine administrated
Study NCT02355834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IBD nurse intervention
Description: Two IBD nurse specialists at each centre (8 in total) will deliver the IBD nurse intervention
Study NCT06552026 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repeated transcranial magnetic stimulation
Description: repetitive transcranial magnetic stimulation by use of high-frequency (10 Hz) left-side DLPFC stimulation is currently widely used in the treatment of depression17.Intermittent theta burst stimulation (iTBS) is a newer form of rTMS that can be delivered with shorter duration of stimulation sessions and apparent efficacy at lower stimulation intensities18. Both 10 Hz and intermittent theta burst stimulation pulses have an excitatory effect on cortical excitability
Study NCT06552026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repeated transcranial magnetic stimulation
Description: repetitive transcranial magnetic stimulation by use of high-frequency (10 Hz) left-side DLPFC stimulation is currently widely used in the treatment of depression17.Intermittent theta burst stimulation (iTBS) is a newer form of rTMS that can be delivered with shorter duration of stimulation sessions and apparent efficacy at lower stimulation intensities18. Both 10 Hz and intermittent theta burst stimulation pulses have an excitatory effect on cortical excitability
Study NCT02295449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biopsy sample performed after the SonoVue® injection
Study NCT00639379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A toric
Description: silicone hydrogel toric lens, 2 wk replacement, daily wear
Study NCT00639379 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: alphafilcon A toric
Description: hydrogel toric lens, 2 wk replacement, daily wear
Study NCT03105947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coconut oil
Description: 50g extravirgin coconut oil daily for four weeks
Study NCT01567085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Study NCT01452087 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
Study NCT00115531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.
Study NCT00115531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: High Dose Influenza Fluzone® Vaccine (60 µg HA / viral strain; 180 µg/0.5 mL dose) will be administered to Arm 2: 200 subjects intramuscularly on Day 0.
Study NCT01996995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser pulse therapy
Study NCT01996995 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Sham procedure
Study NCT03076242 — intervention group
Intervention type: OTHER
Intervention: GEM Registry
Description: Men with a personal history of PCA; Unaffected males who are at higher risk for prostate cancer
Study NCT02545192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Field Magnetic Stimulation
Description: The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1000Hz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. A fully detailed description of the electromagnetic field distribution and waveform has been presented in the IDE submission to the FDA (and determined to be a non-significant risk device).
Study NCT02545192 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low Field Magnetic Stimulation
Description: The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1000Hz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. A fully detailed description of the electromagnetic field distribution and waveform has been presented in the IDE submission to the FDA (and determined to be a non-significant risk device).
Study NCT03426150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPP-ACP
Description: The surfaces of specimens were pretreated with CPP-ACP for 3 min
Study NCT03426150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The surfaces of specimens were pretreated with deionized water for 3 min
Study NCT03530228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan (C1)
Description: Tegoprazan QD, oral administration. Treatment A
Study NCT03530228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan (C1)
Description: Tegoprazan QD, oral administration. Treatment B
Study NCT03530228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Tegoprazan (C1)
Description: Tegoprazan BID, oral administration
Study NCT03530228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan (C2)
Description: Tegoprazan QD, oral administration, for 7 days. Group 1
Study NCT03530228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan (C2)
Description: Tegoprazan QD, oral administration, for 7 days. Group 2
Study NCT03530228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole (C2)
Description: Esomeprazole QD, oral administration, for 7 days. Group 3
Study NCT03530228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan (C3)
Description: Tegoprazan QD, oral administration
Study NCT03105947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Butter
Description: 50g butter daily for four weeks
Study NCT03105947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Description: 50g extra virgin olive oil daily for four weeks
Study NCT03480074 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staple Ligation
Description: Using a stapler that staples the DVC and then cuts it.
Study NCT03480074 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Suture Ligation
Description: Suture the DVC, suspend it to the pubic bone, and then cut.
Study NCT03480074 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Suture Ligation
Description: Cut the DVC, then pinpoint a specific blood vessel needed to sew/suture.
Study NCT02451878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-Couch
Description: e-couch is an online CBT based intervention
Study NCT00296595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition
Study NCT00296595 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition
Study NCT03049566 — intervention group
Intervention type: OTHER
Intervention: preoperative questionnaires
Description: no intervention, cross-sectional survey in a single group
Study NCT02513199 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Radiation is to be delivered to 30-45 Gy in 5 fractions. 40 Gy in 5 fractions will be utilized, unless dose constraints preclude it. Treatment will optimally be delivered every other day with no more than 3 fractions per week. The ideal treatment team will be less than 15 total days.
Study NCT02513199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE
Description: two sessions of standard TACE with ethiodol separated by a 4-week interval.
Study NCT00766220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SIR-spheres Agent Administration
Description: SIR-Spheres, resin microspheres containing pure Beta emitter Yttrium-90, given through femoral catheter over 10 minutes.
Study NCT00766220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 400 mg/m2 by vein over 2 hours once a week.~Cetuximab infusions will be continued weekly at a dose of 250 mg/m2 unless toxicity necessitates interruptions.
Study NCT00883233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene BPO Gel standard daily overnight application
Description: Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week
Study NCT00883233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene-BPO 3-hour daily application before bedtime
Description: Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks
Study NCT00883233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene-BPO Gel every other day application
Description: Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks
Study NCT00883233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene-BPO Gel standard+Cetaphil® Moisturizing Lotion
Description: Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil® Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks
Study NCT04583657 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Eggs
Description: Consumption of two eggs (control or test) per day during three months
Study NCT00766220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 350 mg/m2 (or 300 mg/m2 in patients who are greater or equal to 70 years of age, or have an ECOG PS of 2 or have had prior pelvic and/or abdominal irradiation), by vein over 90 minutes, every three weeks.
Study NCT02855554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance (CMR) imaging techniques
Description: Evaluation of clinical potential of fast quantitative myocardial tissue characterization using recently emerged CMRI techniques to aid the diagnosis, treatment, and follow up of patients with myocardial diseases.
Study NCT04583657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs
Description: Consumption of two eggs (control or test) per day during three months
Study NCT03408665 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 3 sessions at least, up to 6. Neither specifc device is imposed.
Study NCT00833937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg tablets
Description: 1 x 10 mg
Study NCT00833937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMBIEN® 10 mg tablets
Description: 1 x 10 mg
Study NCT01944072 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic exercise training intensity
Study NCT05367986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electro-acupuncture
Description: Electro-acupuncture was given at the Zusanli (ST36), Guanyuan (CV4), and Qihai (CV6) acupoints, twice a day for 30 minutes, and for 5 days in total.~1. Acupoints were selected as follows. (1) Zusanli (ST36) belongs to zuyangming stomach meridian. It is located on the anterolateral part of the lower leg 3 inches (4 horizontal fingers) below the eye of the external knee between the fibula and the tibia, and a horizontal finger (middle finger) width from the front edge of the tibia. (2) Guan yuan (CV4) is located 3 inches below the umbilicus, on the midline of the abdomen. (3) Qihai (CV6) is located 1.5 inches below the umbilicus on the midline.~2. Acupuncture and electro-acupuncture methods were performed as follows. Participants were in the supine position, and needles was inserted in the skin . After the participant has acid, numbness, swelling, pain or other feelings, the electro-acupuncture device was connect to the acupuncture needle, the frequency was set to continuous wave.
Study NCT00614393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: IV infusion
Study NCT02981290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellmune
Description: Cellmune will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
Study NCT02981290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CellCept
Description: CellCept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
Study NCT02053805 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PSA
Description: PSA. Serum \& plasma will be stored for future investigations
Study NCT02053805 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IPSS questionnaire
Description: the validated International Prostate Symptom Score
Study NCT02053805 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DRE (Digital Rectal Examination )
Description: physical examination for the prostate gland
Study NCT01649011 — intervention group
Intervention type: BEHAVIORAL
Intervention: Application of the initial evaluation
Description: Initial evaluation involves the application of the previously spanish validated Rolland Morris Questionnaire and the new spanish Oswestry Disability Index
Study NCT01649011 — intervention group
Intervention type: BEHAVIORAL
Intervention: Final application of scales
Description: Application of the previously spanish validated version of the RMQ and the new spanish translation of the ODI 2 weeks after initial evaluation
Study NCT00614393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: IV infusion
Study NCT00556322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alimta or Taxotere
Description: 500mg/m2 / 3 weeks (Alimta) or 75mg/m2 / 3 weeks (Taxotere)
Study NCT00556322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg po daily
Study NCT01915186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dihydroepiandrosterone (DHEA)
Description: DHEA capsules are given at 25mg 3 times a day for 12 weeks
Study NCT01383694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperine
Study NCT03700723 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Resusix
Description: spray-dried solvent/detergent treated plasma (blood product)
Study NCT03700723 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP24 (Frozen Plasma)
Description: plasma frozen within 24 hours of phlebotomy
Study NCT00664014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tablet;15mg/tab;15/30/60mg/day for 7days Plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
Study NCT00664014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
Study NCT02203903 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor associated antigen lymphocytes (TAA-T)
Description: TAA-T may be generated from donors or recipients and will be tested for specificity to 3 tumor antigens commonly found in hematological malignancies (WT1, PRAME, and SURVIVIN,). The goal of this cell infusion will be to initiate an immune response to residual leukemia or lymphoma that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen).
Study NCT04904705 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach
Description: The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach is a cognitive-based approach. This is a person-oriented, performance-solving problem-solving approach that enables strategy acquisition and guided exploration for the acquisition and learning of new skills.~The main objectives of this approach are; define and transfer domain-specific strategies to other motor-based tasks to gain skills, learn problem-solving strategy (goal, plan, do, check) and adapt to other environments (such as home, school).
Study NCT04904705 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Program
Description: Home Program are activities that a participant can apply at home to improve their skills.
Study NCT00711386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK706769
Description: 50mg, 100mg, 200mg, or 400mg
Study NCT02053805 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: urine flow and residual
Description: The post void residual will be recorded by using ultrasound. Creatinine level will be checked.
Study NCT02053805 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: a multiparametric prostate MRI
Description: The MRI will be reported on a 5 point Likert Scale
Study NCT02053805 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: trans-rectal ultra-sound guided prostate biopsy
Description: 12 core Trans-rectal prostatic biopsy for diagnostic purposes
Study NCT03451448 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET/MRI
Description: PET/MRI with USPIO contrast
Study NCT03451448 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI with USPIO contrast
Study NCT01907685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE8062
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous
Study NCT01907685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Pharmaceutical form: solution for infusion~Route of administration: Intravenous